Synthetic peptide corresponding to Human c-Myc (N terminal) (phospho S62). The antiserum was produced against synthesized phosphopeptide derived from human Myc around the phosphorylation site of serine 62 (P-L-SP-P-S). Database link: P01106
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/100 - 1/500.
1/500 - 1/1000. Detects a band of approximately 49 kDa (predicted molecular weight: 49 kDa).
1/40000. Peptide ELISA.
1/50 - 1/100.
FunctionParticipates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.
Involvement in diseaseNote=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors. Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1. Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
Post-translational modificationsPhosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome. Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.
ICC/IF image of ab51156 stained HepG2 cells. The cells were 4% formlaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab51156, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, a goat anti-rabbit DyLight® 488 (IgG; H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Western blot - c-Myc (phospho S62) antibody (ab51156)
All lanes : Anti-c-Myc (phospho S62) antibody (ab51156) at 1/500 dilution
Lane 1 : extracts from 293 cells treated
with 40nM Forskolin for 30min, with phosphopeptide Lane 2 : extracts from 293 cells treated with 40nM Forskolin for 30min, without phosphopeptide
Predicted band size : 49 kDa Observed band size : 49 kDa
Immunohistochemical analysis of c-Myc (phospho S62) expression in paraffin-embedded human breast carcinoma tissue using 1/50 ab51156. left: untreated sample. Right: sample treated with phosphopeptide.
References for Anti-c-Myc (phospho S62) antibody (ab51156)
This product has been referenced in:
Ma L et al. Trap Effect of Three-Dimensional Fibers Network for High Efficient Cancer-Cell Capture. Adv Healthc Mater4:838-43 (2015).
Read more (PubMed: 25645204) »
Zhang W et al. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1. Oncotarget6:5253-62 (2015).
Read more (PubMed: 25650660) »